Understanding Early Onset Breast Cancer, Part II

Engaging with Patients at Risk for Early Onset Breast Cancer


Early onset breast cancer, defined as breast cancer occurring in women under the age of 45, accounts for approximately 10% of new breast cancer cases in the United States. Younger women tend to experience more aggressive disease, higher risk of recurrence and death, and more long-term survivorship issues than older women.

This course explores tools and approaches to engaging with patients who have an increased risk of developing early onset breast cancer, including: risk assessment and risk reduction strategies; effective patient-provider communication techniques; understanding genetic counseling and testing; the impact of health disparities; and special considerations for survivors of early onset breast cancer.

The learning objectives are to:

  • Identify at least 3 of the most widely used/validated tools for assessing breast cancer risk that can be used in the absence of tools validated specifically for early onset breast cancer.
  • Acquire effective communication tools and techniques to employ in patient interactions to discuss early onset breast cancer risk.
  • Interpret trends in disparities and acknowledge the role multiple factors, including provider-level bias, can play in perpetuating disparities and identifying ways to mitigate this impact.
  • Identify new trends in genetic counseling and testing related to early onset breast cancer.

This is the second course in a two-course series. We recommend that you complete the first course, Part 1: Risk Factors for Early Onset Breast Cancer before beginning this course.

Physicians can purchase the eModule, access it at the link below, and receive CME credit once they achieve 80% or higher on the posttest.

Access Course


ACCME Accreditation

The American College of Obstetricians and Gynecologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)TM

The American College of Obstetricians and Gynecologists designates this enduring activity for a maximum of 7 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s)

The American College of Obstetricians and Gynecologists designates this enduring activity for a maximum of 7 Category 1 College Cognate Credit. The College has a reciprocity agreement with the AMA that allows AMA PRA Category 1 CreditsTM to be equivalent to College Cognate Credits.

ANCCCA Accreditation

This nursing continuing professional development activity was approved by the Maryland Nurses Association, which is an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation (ANCCCA).

Evaluation Survey

Complete the course evaluation survey. Thank you for your feedback!

Conflict of Interest Disclosure

This project was supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) under cooperative agreement number 6 NU38OT000287-02-02. All authors, contributors, reviewers, and staff have submitted a conflict of interest disclosure statement, and any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. This policy, along with ACOG’s Privacy Policy, can be found on

Conflict of interest disclosure for faculty, planning committee, reviewers, and staff:

  • Anne Arnold, MSEd, MA: Owner, Red Thread Consulting, LLC
  • David Chelmow, MD: Editor in Chief for Medscape Ob/Gyn Reference; ABOG Board of Directors
  • Amy Davis, DO: Owns stock in Teva Pharmaceuticals
  • Andrea Forman, MS: Consultant: Invitae; Speaker: Astra Zeneca
  • Rachel Gorham, NP: Consultant: Myriad Genetics
  • Mallory Kremer, MD: Contributor to quarterly practical reviews Internal Medicine, Oakstone Publishing; Participant on March of Dimes grant
  • Allison Kurian, MD: Research funding, Myriad Genetics
  • Karen Smith, MD: Spouse: Stock in Abbvie and Abbott Labs; Research Funding: Pfizer; NCCN and NCI PDQ guideline panels; ASCO survivorship guidelines advisory group; Employed by Johns Hopkins; institution collaborates with Emocha mobile health on app.

All other faculty, planning committee members, reviewers and staff have no conflict of interest to disclose relative to the content of the presentation.